Edwards Lifesciences Corp (EW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,069,400 | 978,200 | 687,900 | 356,400 | 4,169,700 |
| Depreciation Amortization | 156,600 | 113,900 | 74,700 | 36,600 | 155,200 |
| Income taxes - deferred | -117,600 | -63,200 | -45,200 | -24,300 | -323,400 |
| Accounts receivable | -23,000 | -55,400 | -68,600 | -43,700 | 121,200 |
| Other Working Capital | 154,600 | -99,700 | -292,400 | -114,000 | -259,300 |
| Other Operating Activity | 355,200 | 270,500 | 214,200 | 69,400 | -3,321,100 |
| Operating Cash Flow | $1,595,200 | $1,144,300 | $570,600 | $280,400 | $542,300 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -260,200 | -162,800 | -105,300 | -56,000 | -252,400 |
| Net Acquisitions | -25,100 | -19,600 | -17,000 | -3,000 | -1,108,000 |
| Purchase Of Investment | -3,199,900 | -2,358,200 | -1,325,900 | -647,300 | -1,006,100 |
| Sale Of Investment | 2,841,800 | 2,163,600 | 1,471,700 | 845,600 | 4,785,000 |
| Purchase Sale Intangibles | N/A | N/A | N/A | N/A | -30,000 |
| Other Investing Activity | -69,500 | -137,600 | -110,300 | -54,000 | -105,600 |
| Investing Cash Flow | $-712,900 | $-514,600 | $-86,800 | $85,300 | $2,312,900 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 174,100 | 141,800 | 107,100 | 49,900 | 179,500 |
| Common Stock Repurchased | -893,400 | -852,800 | -264,100 | -258,600 | -1,159,400 |
| Other Financing Activity | -237,500 | -234,400 | -48,300 | -49,300 | -3,100 |
| Financing Cash Flow | $-956,800 | $-945,400 | $-205,300 | $-258,000 | $-983,000 |
| Exchange Rate Effect | -44,800 | -48,300 | -47,300 | -17,700 | 38,600 |
| Beginning Cash Position | 3,058,800 | 3,058,800 | 3,058,800 | 3,058,800 | 1,148,000 |
| End Cash Position | 2,939,500 | 2,694,800 | 3,290,000 | 3,148,800 | 3,058,800 |
| Net Cash Flow | $-119,300 | $-364,000 | $231,200 | $90,000 | $1,910,800 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,595,200 | 1,144,300 | 570,600 | 280,400 | 542,300 |
| Capital Expenditure | -260,200 | -162,800 | -105,300 | -56,000 | -252,400 |
| Free Cash Flow | 1,335,000 | 981,500 | 465,300 | 224,400 | 289,900 |